Charcot-Marie-Tooth Disease Type 1E (CMT1E): Comprehensive Disease Characterization Report

Target Disease: Charcot-Marie-Tooth Disease Type 1E MONDO ID: MONDO:0007311 | OMIM: #118300 | Gene: PMP22 (HGNC:9118, 17p12) Category: Rare inherited demyelinating peripheral neuropathy

Summary

Charcot-Marie-Tooth disease type 1E (CMT1E) is a rare, autosomal dominant demyelinating hereditary motor and sensory neuropathy caused by coding point mutations and small insertions/deletions (indels) in the PMP22 gene on chromosome 17p12. It is molecularly distinct from its two more common allelic disorders that arise from copy-number changes at the same locus: CMT1A (1.4-Mb PMP22 duplication) and hereditary neuropathy with liability to pressure palsies / HNPP (PMP22 deletion). Clinically, CMT1E is frequently more severe than CMT1A and is distinguished by a high frequency of sensorineural hearing loss (>40% of patients in a large Korean cohort), with a phenotypic spectrum that extends into the severe, early-onset Dejerine-Sottas syndrome (DSS) range. Point mutations in PMP22 account for less than 5% of all CMT1 cases, making CMT1E a genuinely rare subtype within an already uncommon disease group (overall CMT prevalence ~1 in 2,500).

Mechanistically, CMT1E is a protein-misfolding / toxic gain-of-function (and dominant-negative) disorder. Most pathogenic substitutions fall within the conserved transmembrane domains of the tetraspan membrane protein PMP22. Mutant PMP22 misfolds, fails to traffic to the plasma membrane, and is retained in the endoplasmic reticulum (ER) and Golgi apparatus, where it forms aggresome-like structures surrounded by molecular chaperones and lysosomes. These aggregates are cleared by autophagy, and their accumulation drives Schwann-cell proteostatic stress, apoptosis, and mis-trafficking of cholesterol (retained with mutant PMP22 in the Golgi, reducing plasma-membrane cholesterol needed for myelin). The downstream consequence is dysmyelination/demyelination of peripheral nerves with secondary length-dependent axonal loss — producing the classic distal, symmetric, progressive sensorimotor phenotype.

There is no approved disease-modifying therapy for CMT1E (or any CMT). Management is entirely supportive — rehabilitation, orthotics, corrective surgery, symptom control, and genetic counseling. Because CMT1E is a point-mutation/proteostasis disease, therapies developed for the gene-dosage disorder CMT1A (e.g., ascorbic acid, PMP22 silencers) are not directly applicable; instead, proteostasis-directed strategies — exemplified preclinically by curcumin, which partially rescues the Trembler-J mouse — are the mechanism-matched experimental leads. The faithful natural mouse models Trembler (Tr) and Trembler-J (TrJ) carry Pmp22 point mutations (TrJ carries the human CMT1E Leu16Pro substitution) and recapitulate the dysmyelinating pathology, providing a strong platform for mechanistic and therapeutic study.

Key Findings

Finding 1 — CMT1E is defined by PMP22 point mutations and is more severe than CMT1A, often with deafness

CMT1E is caused by coding point mutations or small indels in PMP22, in contrast to CMT1A (whole-gene duplication) and HNPP (whole-gene deletion). In a Korean cohort of 850 CMT families that were negative for the 17p12 duplication, whole-exome and targeted sequencing identified 14 pathogenic/likely pathogenic PMP22 point mutations across 21 families. Most mutations localized to the conserved transmembrane domains of the protein. Critically, >40% of CMT1E patients showed hearing loss, and both the physical and electrophysiological severity of CMT1E exceeded that of CMT1A, more closely resembling MPZ-related CMT1B (PMID: 35886002). As the authors state: "point mutations or small insertions and deletions (indels) usually cause CMT type 1E (CMT1E) or HNPP" and "more than 40% of the CMT1E patients showed hearing loss. Physical and electrophysiological symptoms of the CMT1E patients were more severely damaged than those of CMT1A."

The rarity of this mechanism is quantified: "Point mutations in the Peripheral Myelin Protein 22 (PMP22) gene comprise less than 5% of the Charcot-Marie-Tooth (CMT) type 1 cases" (PMID: 34332267).

Synonyms / alternative names: CMT1E; Charcot-Marie-Tooth neuropathy type 1E; CMT1 with deafness; PMP22-related CMT1 (point mutation type); demyelinating CMT1E. The severe end of the PMP22 point-mutation spectrum overlaps clinically with Dejerine-Sottas syndrome (DSS) and congenital hypomyelinating neuropathy. Information is derived from aggregated disease-level resources (OMIM, Orphanet) combined with clinical cohort and family studies rather than EHR-derived individual data.

Finding 2 — Mechanism: mutant PMP22 misfolds, is retained in the ER/Golgi, forms aggresomes cleared by autophagy, and disrupts Schwann-cell cholesterol trafficking

The core pathophysiology is a proteostatic / trafficking defect. In Trembler-J (TrJ, Leu16Pro PMP22) mouse nerves, PMP22 has an extended half-life and forms aggresome-like structures surrounded by molecular chaperones and lysosomes; aggresome clearance is enhanced by autophagy activation and blocked by autophagy inhibition (PMID: 14627652): "PMP22 has an extended half-life and forms aggresome-like structures that are surrounded by molecular chaperones and lysosomes" via "a mechanism that is enhanced when autophagy is activated and is primarily prevented when autophagy is inhibited."

The trafficking lesion is specific to the transmembrane domains: "disease-related missense mutations within transmembrane domains of PMP22 disturb intracellular protein trafficking leading to accumulation of the mutant protein in the endoplasmic reticulum/Golgi compartment" (PMID: 10625337).

A key downstream consequence is disrupted lipid handling: in TrJ Schwann cells, cholesterol is retained with TrJ-PMP22 in the Golgi, with a corresponding reduction in plasma-membrane cholesterol, and cholesterol supplementation improved myelination in PMP22-deficient DRG explants (PMID: 32511821): "cholesterol was retained with TrJ-PMP22 in the Golgi, alongside a corresponding reduction in its plasma membrane level." Because cholesterol is an essential structural lipid of compact myelin, its sequestration provides a direct biochemical link between the misfolded protein and the failure of myelination.

Finding 3 — Epidemiology: CMT is the commonest inherited neuropathy (~1/2,500); CMT1E is a rare PMP22-point-mutation subtype

Overall CMT population prevalence is ~1 in 2,500 (PMID: 27584852; PMID: 38784904): "Charcot-Marie-Tooth disease (CMT) is one of the commonest inherited neuromuscular diseases with a population prevalence of 1 in 2500." Within CMT, demyelinating forms dominate. In the Italian National CMT Registry (n=1,012 registered; 711 genetically diagnosed), "Demyelinating CMT (65.3%) was more common than axonal CMT2 (24.6%) and intermediate CMT (9.0%). The PMP22 duplication was the most frequent mutation (45.2%)" (PMID: 37170966). The same registry ranked CMT1E among the most disabling subtypes: "CMT4A was the most disabling type, followed by CMT4C and CMT1E."

CMT1E's rarity is reinforced by cohort data: point mutations comprise <5% of CMT1 (PMID: 34332267), and in some populations (e.g., a Chinese Han cohort of 77 CMT1 families) no point mutations were detected among duplication/deletion-negative probands (PMID: 25522693).

Finding 4 — Trembler and Trembler-J mice are faithful natural point-mutation models; the human Trembler mutation causes Dejerine-Sottas with deafness

The Trembler-J mouse is a natural model carrying a genuine human CMT1E mutation: "Trembler J (TrJ) mice carry the same Leu16Pro amino acid substitution in the PMP22 protein that is present in families diagnosed with CMT1E" (PMID: 42105803). TrJ mice display demyelination, aggresome formation, extracellular-matrix remodeling with MMP-2/-9-expressing macrophage infiltration (PMID: 12421361), and respiratory/phrenic-nerve myelin defects with axonal atrophy (p<0.0001) plus diaphragm remodeling (PMID: 42105803).

Comparative profiling shows that point mutations act through a distinct mechanism from gene-dosage changes: across Pmp22-null, Pmp22-overexpressing, and Trembler mice, "the three Pmp22 mutants exhibited distinct profiles of gene expression, suggesting different disease mechanisms" (PMID: 15755691). This is a central caveat for therapy translation (see Finding 7).

In humans, the classic Trembler (Gly150Asp) substitution produces severe disease: "We report two cases of DSS [Dejerine-Sottas syndrome] in a mother and son with the Trembler mutation, with associated findings of hearing loss and cognitive impairment" (PMID: 35974257), underscoring that PMP22 point mutations can drive the severe end of the demyelinating spectrum.

Finding 5 — No disease-modifying therapy exists; management is supportive; curcumin rescues the Trembler-J phenotype preclinically

"Disease-modifying therapies are not yet available for any form of CMT. Management includes rehabilitative approaches such as muscle strength training and orthotic devices, surgical interventions, symptom relief and anticipatory monitoring of associated complications" (PMID: 41571707).

The mechanism-matched preclinical lead is curcumin, which targets the ER-retention/aggregation-induced apoptosis specific to mutant PMP22: "oral administration of curcumin partially mitigates the severe neuropathy phenotype of the Trembler-J mouse model in a dose-dependent manner. Administration of curcumin significantly decreases the percentage of apoptotic Schwann cells and results in increased number and size of myelinated axons" (PMID: 17701891). Emerging strategies under investigation for the broader CMT field include PMP22 silencers (for CMT1A), HDAC6 inhibitors, and unfolded-protein-response modulation (PMID: 40014417).

Finding 6 — Clinical picture and diagnosis: length-dependent progressive sensorimotor demyelinating neuropathy; NCS + genetic testing

"All forms of CMT result in length-dependent, progressive axonal loss that correlates with clinical impairments such as distal upper and lower limb weakness, musculoskeletal deformity, absent deep tendon reflexes and distal sensory deficits" (PMID: 41571707). Characteristic features include pes cavus, hammertoes, foot drop, distal muscle atrophy, and reduced quality of life across physical, emotional, and social domains (physical being most disabling).

Diagnosis requires "a detailed family history, comprehensive clinical evaluation, nerve conduction studies, and relevant genetic testing" (PMID: 42563944). Demyelinating CMT1 shows uniformly slowed motor nerve conduction velocity (typically <38 m/s). CMT1E is confirmed by identifying a PMP22 point mutation/indel after the PMP22 duplication has been excluded — usually via MLPA (to exclude duplication/deletion) followed by Sanger sequencing or NGS gene panels / WES (PMID: 35886002; PMID: 32506583). Pediatric CMT prevalence estimates range from 9.7 to 82 per 100,000 (PMID: 42563944). CMT can also involve smooth muscle, causing diaphragmatic and gastrointestinal (esophageal) dysmotility (PMID: 40270660).

Finding 7 — Genetics: autosomal dominant with frequent de novo mutations, mutational hotspots, and markedly variable expressivity

CMT1E follows autosomal dominant inheritance. In the Korean cohort, "High frequencies of de novo mutations were observed, and the mutation sites of c.68C>G and c.215C>T were suggested as the mutational hotspots" (PMID: 35886002). Most mutations lie in conserved transmembrane domains and produce a bimodal early-onset-severe / late-onset-mild phenotype.

Expressivity is highly variable, even within a single family: a Portuguese family carrying p.Trp28Cys ranged "from asymptomatic to mild complaints of distal limb numbness and gait difficulties, with the age of onset of symptoms ranging from mid-twenties to late-sixties" and without disability or hearing loss (PMID: 34332267) — in stark contrast to the severe DSS-with-deafness produced by the Trembler mutation (PMID: 35974257). This demonstrates that the specific variant, and its position within the protein, is a major determinant of severity.

Importantly, dosage-model therapies do not translate to point-mutation disease: ascorbic acid, which benefited CMT1A transgenic mice, "in three 1-year trials... had no benefit in human beings" (PMID: 21393063), and high-quality evidence confirms no meaningful benefit in CMT1A (PMID: 26662471). This negative result cautions strongly against extrapolating CMT1A-directed therapies to CMT1E.

Finding 8 — Anatomical/cellular targeting: Schwann-cell-autonomous demyelination of peripheral nerves, ER/Golgi as the subcellular site

The primary affected cell is the myelinating Schwann cell (CL:0002573); the structural target is compact PNS myelin (GO:0043209), with mutant PMP22 pathology localized to the endoplasmic reticulum (GO:0005783) and Golgi (GO:0005794) and cleared via lysosomes/autophagosomes (PMID: 14627652; PMID: 10625337; PMID: 32511821). Affected anatomy is the peripheral nervous system (UBERON:0000044) — including the sciatic (UBERON:0001322) and phrenic (UBERON:0002385) nerves — in a bilateral, symmetric, length-dependent distribution, with secondary axonal loss, musculoskeletal deformity, auditory (sensorineural hearing loss) involvement, and uncommon respiratory/GI smooth-muscle involvement (PMID: 41571707; PMID: 42105803; PMID: 40270660). PMP22 additionally modulates store-operated calcium channel activity, implicating altered Schwann-cell Ca²⁺ handling in the mechanism (PMID: 31213528).

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. A germline (or frequently de novo) heterozygous point mutation / small indel in PMP22 (17p12), typically within a conserved transmembrane domain (hotspots c.68C>G, c.215C>T), leads to production of a misfolded PMP22 protein. (demonstrated — PMID: 35886002)
2. Misfolded PMP22 fails to traffic to the Schwann-cell plasma membrane and is retained in the ER and Golgi apparatus. (demonstrated — PMID: 10625337)
3. ER/Golgi-retained mutant PMP22 has an extended half-life and aggregates into aggresome-like structures surrounded by chaperones and lysosomes. (demonstrated in model — PMID: 14627652)
4. Aggresomes are cleared by autophagy; when this proteostatic capacity is overwhelmed, Schwann-cell stress accumulates. (demonstrated in model — PMID: 14627652)
5. In parallel (branch), mutant PMP22 sequesters cholesterol in the Golgi, reducing plasma-membrane cholesterol required for compact myelin assembly. (demonstrated in model — PMID: 32511821)
6. Proteostatic stress and lipid mis-trafficking result in Schwann-cell apoptosis and impaired myelination. (demonstrated in model; apoptosis reversible by curcumin — PMID: 17701891)
7. Additional contributing branch: altered PMP22-dependent store-operated Ca²⁺ handling and MMP-2/-9-driven extracellular-matrix remodeling (macrophage-mediated) contribute to nerve pathology. (inferred / partly demonstrated — PMID: 31213528, PMID: 12421361)
8. Schwann-cell dysfunction causes dysmyelination/demyelination of peripheral nerves (compact myelin, GO:0043209). (demonstrated)
9. Demyelination leads to uniformly slowed nerve conduction and secondary, length-dependent axonal degeneration. (demonstrated — PMID: 41571707)
10. Axonal loss manifests clinically as distal, symmetric, progressive weakness and sensory loss, pes cavus/hammertoes, areflexia, foot drop — and, in many CMT1E patients, sensorineural hearing loss (a distinguishing feature). (demonstrated — PMID: 35886002, PMID: 41571707)

 PMP22 point mutation (TM domain)
    │  leads to
    ▼
   Misfolded PMP22 protein
    │  retained in
    ▼
      ER / Golgi ──────────────┐
│  aggregates          │ sequesters
▼                      ▼
  Aggresomes            Cholesterol trapped in Golgi
   │ cleared by             │ ↓ plasma-membrane cholesterol
   ▼ autophagy              ▼
 Proteostatic stress ──► Schwann-cell apoptosis ◄── impaired myelin lipids
    │  (+ Ca²⁺ dysregulation, MMP/ECM remodeling)
    ▼
  Dysmyelination / demyelination of peripheral nerves
    │  leads to
    ▼
  Slowed conduction + secondary axonal loss
    │  manifests as
    ▼
  Distal progressive sensorimotor neuropathy ± deafness

Upstream vs downstream: The mutation and protein misfolding/ER-Golgi retention are the upstream initiating events; aggresome formation, cholesterol sequestration, Ca²⁺ dysregulation, and ECM remodeling are intermediate Schwann-cell-autonomous processes; demyelination, secondary axonal loss, and the clinical phenotype are downstream. The mechanism is best classified as a toxic gain-of-function / dominant-negative proteostasis disease — fundamentally different from the gene-dosage mechanism of CMT1A and HNPP, which is why CMT1A-directed therapies (ascorbic acid, PMP22-lowering) are not expected to help CMT1E.

Cell types (CL): myelinating Schwann cell (CL:0002573); infiltrating macrophage (CL:0000235). Biological processes (GO): myelination (GO:0042552); ensheathment of neurons / compact myelin (GO:0043209); ER-associated protein catabolic process / ERAD; autophagy (GO:0006914); protein folding (GO:0006457); cholesterol transport (GO:0030301); apoptotic process (GO:0006915). Cellular components (GO): ER (GO:0005783); Golgi apparatus (GO:0005794); lysosome (GO:0005764); aggresome (GO:0016235).

Section-by-Section Findings

1. Disease Information

CMT1E is an autosomal dominant demyelinating hereditary motor and sensory neuropathy caused by PMP22 coding point mutations. Identifiers: MONDO:0007311; OMIM #118300; gene PMP22 (HGNC:9118); chromosome 17p12. Orphanet groups it under CMT1/PMP22-related neuropathy. Synonyms: Charcot-Marie-Tooth neuropathy type 1E; CMT1 with deafness; PMP22 point-mutation CMT1. Information derives from aggregated disease-level resources plus clinical cohort/family studies, not EHR data.

2. Etiology

Primary cause: heterozygous germline (frequently de novo) point mutation or small indel in PMP22, usually in a transmembrane domain (PMID: 35886002). Genetic risk factors: the specific pathogenic PMP22 variant is causal and largely deterministic; the exact variant is the main modifier of severity (variable expressivity — PMID: 34332267). Environmental risk/protective factors and gene-environment interactions: none established; this is a monogenic Mendelian disorder. Neurotoxic drugs (e.g., vincristine) are a general precaution in CMT but not specifically characterized for CMT1E. No protective alleles identified.

3. Phenotypes

Onset: ranges from congenital/infantile (severe, DSS-like) to late-adult (mild), reflecting bimodal expressivity. Progression: slowly progressive, chronic. QoL: reduced across physical, emotional, and social domains, with the physical domain most disabling (PMID: 41571707).

4. Genetic / Molecular Information

Causal gene: PMP22 (OMIM 601097; HGNC:9118), encoding a 22-kDa tetraspan integral membrane protein of compact PNS myelin (PMID: 11002284). Variant types: missense (predominant, transmembrane domains), plus small indels; classified pathogenic/likely pathogenic per ACMG/AMP. Representative variants: hotspots c.68C>G and c.215C>T (PMID: 35886002); p.Trp28Cys (mild, Portuguese family — PMID: 34332267); Leu16Pro (TrJ / CMT1E); Gly150Asp (Trembler / DSS — PMID: 35974257). Allele frequency: pathogenic variants are private/rare (absent or extremely rare in gnomAD). Origin: germline; frequent de novo. Functional consequence: toxic gain-of-function / dominant-negative via misfolding, not haploinsufficiency. Modifier genes/epigenetics: none established; the causal variant itself is the principal severity determinant. Chromosomal abnormalities:* none (point-mutation disease; distinct from the CNVs underlying CMT1A/HNPP).

5. Environmental Information

No environmental, lifestyle, or infectious contributors are established. CMT1E is monogenic and Mendelian. General neurotoxin avoidance (e.g., vincristine) applies to CMT broadly.

6. Mechanism / Pathophysiology

See the Mechanistic Model section above for the ordered causal chain, branch points, and ontology terms. Key steps: transmembrane-domain misfolding → ER/Golgi retention → aggresome formation cleared by autophagy → cholesterol sequestration and Ca²⁺ dysregulation → Schwann-cell apoptosis → dysmyelination → secondary axonal loss → clinical neuropathy with deafness.

7. Anatomical Structures Affected

Primary: peripheral nerves (UBERON:0000044), especially motor/sensory nerves of distal limbs; sciatic (UBERON:0001322) and phrenic (UBERON:0002385) nerves in models. Body systems: peripheral nervous system; secondary musculoskeletal (foot deformity), auditory system (sensorineural hearing loss), and occasionally respiratory/GI smooth muscle. Cell: myelinating Schwann cell (CL:0002573). Subcellular: ER (GO:0005783), Golgi (GO:0005794), lysosome, aggresome. Laterality: bilateral, symmetric, length-dependent.

8. Temporal Development

Onset: bimodal — early-onset severe (infantile/childhood, DSS-like) vs late-onset mild (adult, up to late-sixties). Course: chronic, slowly progressive, lifelong; not episodic or relapsing-remitting (contrast HNPP). Critical periods: developmental myelination is when PMP22 dysfunction is most consequential; early Schwann-cell proteostasis may be a therapeutic window (PMID: 14627652, PMID: 17701891). No spontaneous remission.

9. Inheritance and Population

Inheritance: autosomal dominant; frequent de novo mutations (PMID: 35886002). Penetrance: high but variable expressivity even intrafamilially (PMID: 34332267). Prevalence: CMT overall ~1/2,500 (PMID: 27584852); CMT1E <5% of CMT1 (PMID: 34332267); pediatric CMT 9.7–82/100,000 (PMID: 42563944). Anticipation / mosaicism / founder effects: not established for CMT1E specifically; de novo occurrence is common. Sex ratio: no strong sex bias reported. Consanguinity: not relevant (dominant).

10. Diagnostics

Electrophysiology: nerve conduction studies showing uniform motor NCV slowing (<38 m/s) — hallmark of demyelinating CMT1. Genetic testing algorithm: exclude PMP22 duplication/deletion first (MLPA/CMA), then Sanger or NGS panel / WES to detect the point mutation (PMID: 32506583, PMID: 35886002). Audiometry for hearing loss. Nerve biopsy (rarely needed) shows demyelination and onion-bulb formation. Differential diagnosis: CMT1A (duplication), CMT1B (MPZ), CMTX1 (GJB1), CIDP (acquired), Dejerine-Sottas syndrome. Screening: cascade genetic testing of at-risk relatives; prenatal/preimplantation testing available given a known familial variant.

11. Outcome / Prognosis

Survival: normal or near-normal life expectancy in typical CMT1E; not directly life-limiting, though severe early-onset (DSS) forms carry higher morbidity, and rare respiratory involvement can affect prognosis (PMID: 42105803). Morbidity: significant, chronic disability from progressive weakness, deformity, and sensory loss; CMT1E ranks among the most disabling CMT subtypes (PMID: 37170966). Prognostic factors: specific variant / domain location, age of onset, presence of hearing loss. No validated molecular prognostic biomarkers.

12. Treatment

No disease-modifying therapy (PMID: 41571707, PMID: 40014417). Supportive/rehabilitative (NCIT-type interventions): physical therapy / strength training (NCIT: Physical Therapy), orthoses/AFOs (NCIT: Orthotic Device), occupational therapy, corrective foot surgery, pain management, hearing aids. Strength training showed benefit for timed walking in CMT (PMID: 19588347). Not indicated: ascorbic acid (no benefit in CMT1A; dosage-model therapy — PMID: 21393063, PMID: 26662471). Experimental / mechanism-matched: curcumin (proteostasis/anti-apoptotic; preclinical rescue of TrJ — PMID: 17701891); autophagy enhancers; HDAC6 inhibitors; UPR modulators (PMID: 40014417). PMP22 silencers target CMT1A dosage and are not appropriate for point-mutation CMT1E unless allele-specific.

13. Prevention

No primary prevention (monogenic). Genetic counseling is central: autosomal dominant inheritance with 50% transmission risk, plus de novo recurrence counseling. Reproductive options: prenatal diagnosis and preimplantation genetic testing when the familial variant is known. Tertiary prevention: rehabilitation, orthotics, foot care, fall prevention, and anticipatory monitoring for respiratory/auditory complications.

14. Other Species / Natural Disease

Pmp22 is highly conserved; mouse (NCBI Taxon:10090) orthologue Pmp22 underlies the spontaneous Trembler (Tr) and Trembler-J (TrJ) mutants — naturally occurring dysmyelinating neuropathies that are genuine models of human PMP22 point-mutation disease (PMID: 42105803, PMID: 30685714). No zoonotic potential. Evolutionary conservation of PMP22 function in myelination makes rodent models informative but imperfect (species differences in lesions — PMID: 30685714).

15. Model Organisms

Natural point-mutation mice: Trembler-J (Leu16Pro, the human CMT1E allele) and Trembler (Gly150Asp) (PMID: 42105803, PMID: 15755691). Engineered models: Pmp22-null and Pmp22-overexpressing lines model HNPP and CMT1A respectively, and comparative studies show distinct expression profiles / mechanisms by mutation type (PMID: 15755691). Recapitulation: TrJ faithfully reproduces dysmyelination, aggresome formation, apoptosis, ECM remodeling, and phrenic-nerve/diaphragm pathology. Limitations: rodent lesions differ in some respects from human nerve pathology (PMID: 30685714). In vitro: DRG/Schwann-cell co-cultures and patient-derived iPSC-Schwann cells are relevant for trafficking/proteostasis assays. Resources: MGI, IMSR.

Evidence Base

Consistency of the evidence: Findings converge across independent human cohorts (Korea, Portugal, Italy, China, Brazil), natural mouse models (Trembler/TrJ), and in vitro trafficking studies. The proteostasis/misfolding mechanism is supported by ≥4 independent model/in vitro lines. The one important negative result — ascorbic acid failing in CMT1A RCTs — reinforces (rather than challenges) the conclusion that CMT1E, a distinct proteostasis disorder, requires distinct, mechanism-matched therapy.

Limitations and Knowledge Gaps

1. CMT1E-specific epidemiology is imprecise. No dedicated prevalence/incidence estimate exists for CMT1E; it is inferred as <5% of CMT1. Sex ratio, penetrance quantification, and natural-history data are largely extrapolated from broader CMT/CMT1 datasets.
2. Genotype–phenotype correlation is incomplete. Although variant position (transmembrane vs extracellular) clearly influences severity, no comprehensive map links specific PMP22 residues to hearing loss, onset, or progression rate.
3. Human mechanistic data are limited. Much of the misfolding/aggresome/cholesterol mechanism derives from Trembler/TrJ mice and in vitro systems; direct confirmation in human CMT1E nerve or iPSC-Schwann cells is sparse.
4. No CMT1E-specific therapeutic trials. Curcumin data are preclinical (mouse) only; no human trials in CMT1E. Emerging therapies (HDAC6 inhibitors, UPR modulators, allele-specific silencing) remain unvalidated for point-mutation disease.
5. Hearing-loss mechanism unexplained. The >40% frequency of sensorineural hearing loss is well documented but its cellular basis (cochlear vs auditory-nerve myelination) is not established.
6. Ca²⁺ and ECM contributions (store-operated calcium, MMP-mediated remodeling) are documented in models but their causal weight in human disease is uncertain.

Proposed Follow-up Experiments / Actions

1. Genotype–phenotype registry analysis: Aggregate ClinVar/HGMD PMP22 point-mutation variants with clinical severity and hearing-loss status to build a residue-level severity map, distinguishing transmembrane vs loop-domain effects.
2. Patient-derived iPSC-Schwann-cell models: Generate CMT1E lines (e.g., Leu16Pro, Trp28Cys, Gly150Asp) to confirm ER/Golgi retention, aggresome burden, cholesterol mis-trafficking, and apoptosis in a human context, and to screen proteostasis modulators.
3. Mechanism-matched therapeutic screening: Test autophagy enhancers, chemical chaperones, HDAC6 inhibitors, and UPR modulators against mutant-PMP22 clearance and myelination endpoints in TrJ mice and human iPSC-Schwann cells; advance the most efficacious to CMT1E-specific trial design.
4. Cholesterol-supplementation study: Given Golgi cholesterol sequestration, evaluate dietary/pharmacologic cholesterol or statin-pathway modulation on myelination in TrJ models.
5. Allele-specific silencing: Develop and test ASO/siRNA approaches that selectively suppress the mutant PMP22 allele (preserving wild-type dosage) — the rational silencing strategy for a dominant point-mutation disease.
6. Auditory phenotyping: Systematically characterize the cochlear/auditory-nerve basis of CMT1E hearing loss (audiometry + ABR in patients; cochlear histology in models) to define an underexplored, distinguishing feature.
7. Natural-history cohort: Establish a CMT1E-specific longitudinal cohort (CMTNS, timed walk, QoL, audiometry, respiratory function) to define progression rate and validate outcome measures for future trials.

Report compiled from an autonomous multi-iteration literature investigation (32 papers reviewed; 8 confirmed findings). Evidence types span human clinical/cohort studies, natural and engineered mouse models, and in vitro systems, as annotated throughout.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:40270660 (7 mentions) - Oesophageal Dysmotility in a Patient with Charcot-Marie-Tooth Disease: Report and Literature Review.
• shared terms: disease
• PMID:19588347 (3 mentions) - Rehabilitation interventions for foot drop in neuromuscular disease.
• shared terms: disease

Weighed against this report's own most characteristic terms: pmp22, cmt1e, mutation, loss, model, cmt, hearing, point-mutation, disease, cmt1a, type, trj, cmt1, severe, demyelinating, domain, nerve, mechanism, aggresome, variant.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0002936 (1 mention) - the report calls it "Symptom/sign"; HP calls it Distal sensory impairment
• HP:0001761 (1 mention) - the report calls it "Physical manifestation"; HP calls it Pes cavus
• HP:0001765 (1 mention) - the report calls it "Physical manifestation"; HP calls it Hammertoe
• HP:0001315 (1 mention) - the report calls it "Clinical sign"; HP calls it Diminished deep tendon reflex
• HP:0009830 (1 mention) - the report calls it "Clinical sign"; HP calls it Peripheral neuropathy
• HP:0000407 (1 mention) - the report calls it "Sign / lab (audiometry)"; HP calls it Sensorineural hearing impairment
• HP:0003431 (1 mention) - the report calls it "Lab / electrophysiology"; HP calls it Decreased motor nerve conduction velocity
• HP:0002093 (1 mention) - the report calls it "Sign"; HP calls it Respiratory insufficiency
• HP:0002015 (1 mention) - the report calls it "Symptom"; HP calls it Dysphagia
• HP:0001268 (1 mention) - the report calls it "Sign"; HP calls it Mental deterioration

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: Taxon.